Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology firm, announced that its CEO, Bill Hinshaw, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 a.m. ET. The presentation will focus on Axcella's innovative approach to treating complex diseases with multi-targeted endogenous metabolic modulator compositions. A webcast of the event will be available on the company's website and can be accessed for 90 days post-event. Axcella's pipeline includes therapies for overt hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference.

A webcast of this presentation will be available on the “Investors & News” section of the company’s website, www.axcellatx.com, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Axcella’s website for 90 days following the event.

Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella Therapeutics (Nasdaq: AXLA)
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005465/en/

Jason Fredette

jfredette@axcellatx.com

(857) 320-2236

Source: Axcella Therapeutics

FAQ

When is Axcella's presentation at the H.C. Wainwright BioConnect Conference?

Axcella's presentation will take place on January 10, 2022, at 7:00 a.m. ET.

Who is presenting for Axcella at the conference?

Bill Hinshaw, the President and CEO of Axcella, will be presenting.

Where can I watch Axcella's conference presentation?

The presentation will be available as a webcast on Axcella's website in the 'Investors & News' section.

What is Axcella Therapeutics' focus in biotechnology?

Axcella specializes in developing treatments for complex diseases using endogenous metabolic modulator compositions.

What diseases is Axcella's pipeline targeting?

Axcella's pipeline includes candidates for overt hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis.